Kimberly Warren, MD
Ophthalmology · Dallas, TXNPI 1942239272
Payments from drug & device makers
Across 160 payments — averaging $601.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$93K
- Johnson & Johnson Surgical Vision, Inc.$507
- Alcon$388
- Rxsight Inc$343
- Bausch & Lomb, A Division Of Bausch Health US, LLC$327
- Bausch & Lomb Americas Inc.$282
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,697100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 60 | $93,237 |
| Johnson & Johnson Surgical Vision, Inc. | 10 | $507 |
| Alcon | 23 | $388 |
| Rxsight Inc | 6 | $343 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 16 | $327 |
| Bausch & Lomb Americas Inc. | 8 | $282 |
| Biotissue Holdings Inc. | 6 | $276 |
| Astellas Pharma US Inc | 5 | $149 |
| Ivantis, Inc | 1 | $133 |
| Aerie Pharmaceuticals, Inc. | 5 | $99 |
| Novartis | 3 | $89 |
| Harrow Eye, LLC | 4 | $70 |
| Tarsus Pharmaceuticals, Inc. | 3 | $56 |
| Dompe US, Inc. | 2 | $55 |
| Thea Pharma Inc. | 2 | $38 |
| Oyster Point Pharma, Inc. | 1 | $29 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Apellis Pharmaceuticals, Inc. | 1 | $21 |
| Rayner Intraocular Lenses Limited | 1 | $18 |
| Kala Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$153
- AmnioGraft$153
- Tecnis IOL$152
- IC-8 Apthera IOL$149
- RXSIGHT CONTACT LENS$140
- RXSIGHT INJECTOR CARTRIDGE$140
- RXSIGHT INJECTOR HANDPIECE$140
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$140
- LIGHT ADJUSTABLE LENS (LAL)$140
- Hydrus Microstent$133
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$131
- Tecnis Symfony IOL$122
- Tecnis Multifocal Family of 1-piece IOLS$122
- Tecnis Toric 1-piece IOL$122
How this compares
$96,181 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 112 | $63,724 |
| RestasisCyclosporine | 39 | $52,318 |
| Cyclosporine | 24 | $17,809 |
| CombiganBrimonidine Tartrate/Timolol | 34 | $16,712 |
| Latanoprost | 1,205 | $13,443 |
| ProlensaBromfenac Sodium | 36 | $12,456 |
| VyzultaLatanoprostene Bunod | 33 | $11,996 |
| RhopressaNetarsudil Mesylate | 14 | $10,575 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 68 | $8,723 |
| Prednisolone Acetate | 133 | $7,140 |
| Travoprost | 34 | $6,233 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 13 | $5,112 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 19 | $5,034 |
| Brimonidine Tartrate | 443 | $4,531 |
| Timolol Maleate | 206 | $3,484 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $93,237 | $132,754185 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $327 | $15,09559 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $282 | $11,99633 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $99 | $10,57514 claims |
| AlconSimbrinza | $388 | $5,11213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Dallas
- Ashkan AbbeyDallas$5.7M
- Karl CsakyDallas$4.9M
- Jeffrey WhitmanDallas$1.7M
- Oluwatosin SmithDallas$1.7M
- Davinder GroverDallas$1.3M
- Robert WangDallas$594K
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.